Skeletal Radiology

, Volume 38, Issue 9, pp 841–853

Founders lecture 2007

Metabolic bone disease: what has changed in 30 years?
Review Article

Abstract

Objective

To provide an update on imaging of metabolic bone disease based on new developments, findings, and changing practices over the past 30 years.

Materials and methods

Literature review of osteoporosis, osteomalacia, renal osteodystrophy, Paget’s disease, bisphosphonates, with an emphasis on imaging.

Results

Cited references and pertinent findings.

Conclusions

Significant developments have occurred in the imaging of metabolic bone disease over the past 30 years.

Keywords

Imaging Osteoporosis Osteomalacia Renal osteodystrophy Paget’s disease Bisphosphonates 

References

  1. 1.
    Sambrook P, Cooper C. Osteoporosis. Lancet 2006; 367: 2010–2018.PubMedCrossRefGoogle Scholar
  2. 2.
    Consensus development conference: diagnosis, prophylaxis, and treatment of Osteoporosis. Am J Med 1993; 94: 646–651.Google Scholar
  3. 3.
    Genant HK, Engelke K, Fuerst T, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Minor Res 1996; 11: 707–730.CrossRefGoogle Scholar
  4. 4.
    Baran DT, Faulkner KG, Genant HK, et al. Diagnosis and management of osteoporosis—guidelines for the utilization of bone densitometry. Calcif Tissue Int 1997; 61: 433–440.PubMedCrossRefGoogle Scholar
  5. 5.
    Majumdar S. Magnetic resonance imaging for osteoporosis. Perspective. Skelet Radiol 2008; 37: 95–97.CrossRefGoogle Scholar
  6. 6.
    Melton LJ III. Epidemiology of spinal osteoporosis. Spine 1997; 22(Suppl): S2–S11.CrossRefGoogle Scholar
  7. 7.
    Rapado A. General management of vertebral fractures. Bone 1996; 18(Suppl): 1915–1965.Google Scholar
  8. 8.
    Galibert P, Deramand H, Rosat P, LeGars D. Preliminary note on the treatment of vertebral angioma by percutaneous acrylic vertebroplasty. Neurochirurgie 1987; 33: 166–168.PubMedGoogle Scholar
  9. 9.
    Lapras C, Mottolese C, Deruty R, et al. Percutaneous injection of methyl methacrylate in the treatment of severe vertebral osteoporosis and osteolysis. Ann Chir 1989; 43: 371–376.PubMedGoogle Scholar
  10. 10.
    Mathis JM. Percutaneous vertebroplasty of kyphoplasty: which one do I choose? Perspective. Skelet Radiol 2006; 35: 629–631.CrossRefGoogle Scholar
  11. 11.
    Glorieux FH, Rauch F, Plotkin H, et al. Type V osteogenesis imperfecta: a new form of brittle bone disease. J Bone Miner Res 2000; 15: 1650–1658.PubMedCrossRefGoogle Scholar
  12. 12.
    Cheung MS, Azouz EM, Glorieux FH, Rauch F. Hyperplastic callus formation in osteogenesis imperfecta type V: follow up of three generation over ten years. Skelet Radiol 2008; 37: 465–467.CrossRefGoogle Scholar
  13. 13.
    Nattor A, Loucks AB, Manore MM, Sanborn CF, Sundgot-Borgen J, Warren MP. American College of Sports Medicine Position Stand. The female athlete triad. Med Sci Sports Exerc 2008; 39: 1867–1882.Google Scholar
  14. 14.
    Vande Berg BC, Malghem J, Devuyst O, Maldague BE, Lambert MJ. Anorexia nervosa: correlation appearance between MR appearance of bone marrow and severity of disease. Radiology 1994; 193: 859–864.Google Scholar
  15. 15.
    Tins B, Cassar-Pullicino V. Marrow changes in anorexia nervosa masking the presence of stress fractures on MR imaging. Skelet Radiol 2006; 35: 857–860.CrossRefGoogle Scholar
  16. 16.
    Harrison HE, Harrison HC. Rickets then and now. J Pediatr 1995; 87: 1144.Google Scholar
  17. 17.
    Pitt MJ. Rickets and osteomalacia are still around. Radiol Clin North Am 1991; 29: 97–118.PubMedGoogle Scholar
  18. 18.
    Weissman Y, Hochberg Z. Genetic rickets and osteomalacia. Curr Ther Endocinrol Metab 1994; 5: 492–495.Google Scholar
  19. 19.
    Polisson RP, Martinez S, Khoury M, et al. Calcification of enthesis associated with x-linked hypophosphatemic osteomalacia. N Engl J Med 1985; 313: 1–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Adams JE, Davies M. Intraspinal new bone formation and spinal cord compression in familial hypophosphatemic vitamin D resistant osteomalacia. Am J Med 1986; 61: 1117–1129.Google Scholar
  21. 21.
    Prader VA, Inig R, Vehlinger E, Stalder G. Rachitis, infole, knochen tumors. Helv Pediatr Acta 1959; 14: 554–565.Google Scholar
  22. 22.
    Econs MJ, Drezner MK. Tumor induced osteomalacia; unveiling a new hormone. N Engl J Med 1994; 330: 1679–1681.PubMedCrossRefGoogle Scholar
  23. 23.
    Shimada T, Mizutani S, Muto T, et al. Cloning and characterization of FGF23 as a causative factor or tumor-induced osteomalacia. Proc Natl Acad Sci USA 2001; 98: 6500–6505.PubMedCrossRefGoogle Scholar
  24. 24.
    John MR, Wickert H, Zaar K, et al. A case of neuroendocrine oncogenic osteomalacia associated with a PHEX and fibroblast growth factor–23 expressing sinusidal malignant schwannoma. Bone 2001; 29: 393–402.PubMedCrossRefGoogle Scholar
  25. 25.
    Rowe PSN, de Zoysa PA, Dong R, et al. MEPE, a new gene expressed in bone marrow and tumor causing osteomalacia. Genomics 2000; 67: 54–68.PubMedCrossRefGoogle Scholar
  26. 26.
    Siegel HJ, Rock MG, Inwards C, Sim FH. Phospahturic mesenchymal tumor. Orthopedics 2002; 25: 1279–1281.PubMedGoogle Scholar
  27. 27.
    Avila NA, Skarulis M, Rubino DM, Doppmath JL. Oncogenic osteomalacia: lesion detection by MR skeletal survey. AMJ Roentgenol 1996; 167: 343–345.Google Scholar
  28. 28.
    Seufert J, Ebert K, Muller J, et al. Brief report: octreotide therapy for tumor induced osteomalacia. N Engl J Med 2001; 345: 1883–1888.PubMedCrossRefGoogle Scholar
  29. 29.
    Sundaram M, McCarthy EF. Oncogenic osteomalacia. Skeletal Radiol 2000; 29: 117–124.PubMedCrossRefGoogle Scholar
  30. 30.
    Folpe A, Fanburg-Smith J, Billing S, et al. Most osteomalacia associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Path 2004; 28: 1–30.PubMedCrossRefGoogle Scholar
  31. 31.
    Zink AR, Panzer S, Fesq-Martin M, et al. Evidence for a 7000 year old case of primary hyperparathyroidism (letter). JAMA 2005; 293: 259–372.Google Scholar
  32. 32.
    Ruda JM, Hollenbeaker CS, Stach BC Jr. A systematic review of the diagnosis and treatment of primary hyperparathyroidism, 1995–2003. Otolaryngol Head Neck Surg 2005; 132: 259–372.CrossRefGoogle Scholar
  33. 33.
    Kollaris J, Zarroug AE, Van Hwerden J, et al. Primary hyperparathyroidism in pediatric patients. Pediatrics 2005; 115: 974–980.CrossRefGoogle Scholar
  34. 34.
    Lucas RC. A form of late rickets associated with albuminuria: rickets of adolescents. Lancet 1883; 1: 993.Google Scholar
  35. 35.
    Liu SH, Chu HI. Studies of calcium and phosphorous metabolism with special reference to pathogenesis and effects of dihydrotachysterol and iron. Medicine 1946; 22: 103.Google Scholar
  36. 36.
    Parfitt AM. The actions of parathyroid hormone on bone: relation to bone remodeling and turnover calcium homeostasis and metabolic bone disease. Metabolism 1976; 25: 1157.PubMedCrossRefGoogle Scholar
  37. 37.
    Cameron JS. Dialysis today and tomorrow: history of the treatment of renal failure by dialysis. Oxford: Oxford University Press, 2002. p. 336.Google Scholar
  38. 38.
    Sundaram M, Wolverson MK. The prevalence of skeletal surveys of patients in maintenance hemodialysis. Ann Inteon Med 1982; 97: 780.Google Scholar
  39. 39.
    Cameron JS. The rise and rise of dialysis amyloidosis. A history of the treatment of renal failure by dialysis. Oxford: Oxford University Press, 2002. p. 263.Google Scholar
  40. 40.
    Cameron JS. The rise and fall of aluminum osteodystrophy. A history of the treatment of renal failure by dialysis. Oxford: Oxford University Press, 2002. p. 258.Google Scholar
  41. 41.
    Leone A, Sundaram M, Cerase A, Mognavita N, Tazza L, Marrano P. Destructive spondyloarthropathy of the cervical spine in long-term hemodialyzed patients: a five-year clinical radiological prospective study. Skeletal Radiol 2001; 30: 431–441.PubMedCrossRefGoogle Scholar
  42. 42.
    Cooper C, et al. Update on the epidemiology of Paget’s disease of bone. JBMR 2006; 21: 3–8.CrossRefGoogle Scholar
  43. 43.
    Cundy T. Perspective. Skeletal Radiol 2006; 35: 350–351.PubMedCrossRefGoogle Scholar
  44. 44.
    Kaufmann GA, Sundaram M, McDonald DJ. Magnetic resonance imaging in symptomatic Paget’s disease. Skeletal Radiol 1991; 20: 413–418.PubMedCrossRefGoogle Scholar
  45. 45.
    Sundaram M, Khanna G, El-Khoury G. T1 weighted MR imaging for distinguishing large osteolysis of Paget’s disease from sarcomatous degeneration. Skeletal Radiol 2001; 30: 378–383.PubMedCrossRefGoogle Scholar
  46. 46.
    McNairn JDK, Damron TA, Landas SK, Ambrose JL. Benign tumefactive soft tissue extension from Paget’s disease of bone simulating malignancy. Skeletal Radiol 2001; 30: 157–160.PubMedCrossRefGoogle Scholar
  47. 47.
    Cook GJR, Maisey MN, Fogelman I. Fluorine-18-FDG PET in Paget’s disease of bone. J Nucl Med 1997; 38: 1495–1497.PubMedGoogle Scholar
  48. 48.
    Reid IR. Bisphosphonates. Perspective. Skeletal Radiol 2007; 36: 711–714.PubMedCrossRefGoogle Scholar
  49. 49.
    Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809–1820.PubMedCrossRefGoogle Scholar
  50. 50.
    Bilezikian JP. Osteonecrosis of the jaw—do bisphosphonates pose a risk? N Engl J Med 2006; 155: 2278–2281.CrossRefGoogle Scholar
  51. 51.
    Reid IR, Cundy T. Osteonecrosis of the jaw. Skeletal Radiol 2009; 38: 5–19.PubMedCrossRefGoogle Scholar
  52. 52.
    Bisdao S, Pinho NC, Smolarz A, Sader R, Vogl TJ, Mack MG. Bisphosphonate induced osteonecrosis of the jaws. CT and MRI spectrum of findings in 32 patients. Clin Radiol 2008; 63: 71–77.CrossRefGoogle Scholar
  53. 53.
    Muderis Al M, Azzopardi T, Cundy P. Zebra lines of pamidronate therapy in children. J Bone Joint Surg (Am) 2007; 89: 1151–1516.CrossRefGoogle Scholar

Copyright information

© ISS 2009

Authors and Affiliations

  1. 1.Diagnostic Radiology, MSKCleveland ClinicClevelandUSA

Personalised recommendations